How user knowledge of psychotropic drug withdrawal resulted in the development of person-specific tapering medication
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Coming off psychotropic drugs can cause physical as well as mental withdrawal, resulting in failed withdrawal attempts and unnecessary long-term drug use. The first reports about withdrawal appeared in the 1950s, but although patients have been complaining about psychotropic withdrawal problems for decades, the first tentative acknowledgement by psychiatry only came in 1997 with the introduction of the ‘antidepressant-discontinuation syndrome’. It was not until 2019 that the UK Royal College of Psychiatrists, for the first time, acknowledged that withdrawal can be severe and persistent. Given the lack of a systematic professional response, over the years, patients who were experiencing withdrawal started to work out practical ways to safely come off medications themselves. This resulted in an experience-based knowledge base about withdrawal which ultimately, in The Netherlands, gave rise to the development of person-specific tapering medication (so-called tapering strips). Tapering medication enables doctors, for the first time, to flexibly prescribe and adapt the medication required for responsible and person-specific tapering, based on shared decision making and in full agreement with recommendations in existing guidelines. Looking back, it is obvious that the simple practical solution of tapering strips could have been introduced much earlier, and that the traditional academic strategy of comparisons from randomised trials is not the logical first step to help individual patients. While randomised controlled trials (RCTs) are the gold standard for evaluating interventions, they are unable to accommodate the heterogeneity of individual responses. Thus, a more individualised approach, building on RCT knowledge, is required. We propose a roadmap for a more productive way forward, in which patients and academic psychiatry work together to improve the recognition and person-specific management of psychotropic drug withdrawal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Overall, there has been scant attention paid to the issue of antidepressant tapering previously in the academic literature,48,53–56 which has been focused primarily on starting medication.57”
The cited source says what the claim attributes to it.
In the citing paper
“Self-monitoring can sometimes add an extra dimension, making the tapering more personalised and more robust to manage early withdrawal.9,29”
From Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study (2021) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Apart from the Horowitz–Taylor tapering method,20 and the work of Peter Groot and Jim van Os in the Netherlands,54–56 there seem to be no good studies on how to safely taper patients off these medications.”
In the citing paper
“National guidelines on tapering of antidepressant and other psychotropic medications, if they exist at all, typically are based on ‘expert opinion’, excluding user knowledge and lived experience, and not very helpful when it comes to the actual process of tapering the medication.1,6,13”
From Outcomes of hyperbolic tapering of antidepressants (2023) · cites this paper as [6]
In the citing paper
“As described elsewhere, rate of tapering can be a very important factor and some individuals may be able to come off medications if a slower and more personalised approach is adopted.9”
From Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study (2021) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lack of group-to-individual generalizability is a threat to human subjects research
Fisher, A. J., Medaglia, J. D., & Jeronimus, B. F. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711978115 · Cited by 1,099
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Tolerating Uncertainty — The Next Medical Revolution?
Simpkin, A. L., & Schwartzstein, R. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1606402 · Cited by 521
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
No Shortcuts to Safer Opioid Prescribing
Dowell, D., Haegerich, T., & Chou, R. (2019) · New England Journal of Medicine · doi:10.1056/nejmp1904190 · Cited by 408
Critical Slowing Down as a Personalized Early Warning Signal for Depression
Wichers, M., Groot, P. C., & Psychosystems, E. G. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000441458 · Cited by 399
Self-citationDavies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
Withdrawal reactions from chlordiazepoxide (?Librium?)
Hollister, L. E., Motzenbecker, F. P., & Degan, R. O. (1961) · Psychopharmacologia · doi:10.1007/bf00429621 · Cited by 340
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
Research works printed but not linked: 2
- 44. Scoping about tapering of (specific) antidepressants using tapering strips. Organized by the Dutch National Healthcare Institute, 24 August 2017, Diemen.
- 74. Muzina DJ. Discontinuing an antidepressant? Currenty Psychiatry 2010; 9: 51–60.
Cited by
Guy, A., Brown, M., Lewis, S., & Horowitz, M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320967183 · Cited by 77
Hengartner, M. P., Schulthess, L., Sorensen, A., & Framer, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320980573 · Cited by 74
Framer, A. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125321991274 · Cited by 73
White, E., Read, J., & Julo, S. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320981174 · Cited by 63
Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study
Groot, P. C., & van Os, J. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211039327 · Cited by 38
“Variables collected were: (1) age (in years), (2) sex, (3) type of medication and duration of use prior to tapering, (4) number of attempts to stop medication before using tapering strips, (5) severity of withdrawal symptoms during previous discontinuation attempts without tapering strips on a 1–7 Likert scale (‘Did y…”
BackgroundSelf-citationOutcome of antidepressant drug discontinuation with taperingstrips after 1–5 years
Groot, P. C., & van Os, J. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320954609 · Cited by 35
Self-citationHorowitz, M., & Wilcock, M. (2022) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2020.000080 · Cited by 33
Outcomes of hyperbolic tapering of antidepressants
van Os, J., & Groot, P. C. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231171518 · Cited by 22
Self-citationCooper, R. E., Ashman, M., Lomani, J., Moncrieff, J., Guy, A., Davies, J., Morant, N., & Horowitz, M. (2023) · PLOS ONE · doi:10.1371/journal.pone.0282988 · Cited by 23
“Tapering strips are one example of compounded medication made by a specialist pharmacy in Holland in which increasingly small doses of medication are sealed in plastic strips [22].”
BackgroundVeldmeijer, L., Terlouw, G., van Os, J., Meerman, S. T., Veer, J. V. ‘., & Boonstra, N. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1426475 · Cited by 25
Cooper, R. E., Mason, J., Calton, T., Richardson, J. M., & Moncrieff, J. (2021) · Psychosis · doi:10.1080/17522439.2021.1930119 · Cited by 21
“Tapering strips could be used to reduce, although these are only available in certain countries (Groot & van Os, 2020).”
BackgroundJo, E., Ryu, M., Kenderova, G., So, S., Shapiro, B. B., Papoutsaki, A., & Epstein, D. A. (2022) · CHI Conference on Human Factors in Computing Systems · doi:10.1145/3491102.3502206 · Cited by 22
“Past work has highlighted that patients are often self-motivated to discontinue psychiatric drugs, with or without the support of a provider [24, 28, 60].”
BackgroundEserian, J. K., Blanco, V. P., Mercuri, L. P., Matos, J. D. R., & Galduróz, J. C. F. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115537 · Cited by 15
Boland, M., Higgins, A., Beecher, C., Bracken, P., Burn, W., Cody, A., Framer, A., Gronlund, T., Horowitz, M., Huff, C., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-088266 · Cited by 14
Neuromodulators in the Brain-Gut Axis: their Role in the Therapy of the Irritable Bowel Syndrome
Stănculete, M. F., Dumitrascu, D. L., & Drossman, D. A. (2021) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-4090 · Cited by 22
Psychiatric Deprescribing: A Narrative Review
Harding, S., Ellis, K. A., Boisseau, J., & Petreca, V. G. (2023) · Journal of the American Psychiatric Nurses Association · doi:10.1177/10783903231185353 · Cited by 14
“While randomized controlled trials are necessary to generate evidence for how and when to taper, the experiences and knowledge generated by clients should also play a central role (Framer, 2021; Groot & van Os, 2020; Gupta et al., 2019).”
InfluentialLarsen-Barr, M., & Seymour, F. W. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125321989133 · Cited by 12
Deprescribing NSAIDs: The Potential Role of Community Pharmacists
Amedi, D., & Gazerani, P. (2024) · Pharmacy · doi:10.3390/pharmacy12040116 · Cited by 11
“In the Netherlands, pharmacists have achieved a successful deprescription rate of around 70% for psychotropic drugs with minimal withdrawal symptoms reported [60].”
BackgroundCohen, D., & Recalt, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320964097 · Cited by 15
Jo, E., Zehrung, R., Genuario, K. E., Papoutsaki, A., & Epstein, D. A. (2024) · Proceedings of the ACM on Human-Computer Interaction · doi:10.1145/3686997 · Cited by 14
Frank, D. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103348 · Cited by 8
Depression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
Peer support’s role in helping individuals withdraw from psychiatric medications
Maviglia, M. A., Hume, D., & Cooeyate, N. J. (2023) · Journal of Psychology & Clinical Psychiatry · doi:10.15406/jpcpy.2023.14.00746 · Cited by 5
Oscar, M. M., Boland, M., & Cadogan, C. A. (2025) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2025.06.107 · Cited by 4
Dependence on newer generation antidepressants
Vaaler, A. (2022) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.22.0339 · Cited by 4
Huang, W., Li, X., Huang, S., Huang, S., Xia, H., Guo, Z., Yan, H., Li, Y., & Shang, D. (2025) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2025.103893 · Cited by 3
Un sevrage progressif responsable et sûr à l’aide de Tapering strips
Musso, M., van Os, J., & Groot, P. C. (2022) · L information psychiatrique · doi:10.1684/ipe.2022.2506 · Cited by 4
“Les deux exemples de questionnaires remplis montrent comment cela peut se dérouler en pratique (figure 3 [17]).”
BackgroundSelf-citationAre Psychedelics Ethically Exceptional After All? Some Further Reflections
Cheung, K., Earp, B. D., Patch, K., & Yaden, D. B. (2026) · The American Journal of Bioethics · doi:10.1080/15265161.2026.2637063 · Cited by 1
“In the Netherlands, individual experimentation with SSRI (selective serotonin reuptake inhibitor) tapering led to the development of person-specific tapering strips (Groot and van Os 2020).”
Chandler, M. C. (2022) · Current Psychiatry · doi:10.12788/cp.0284 · Cited by 1
Maviglia, M. A., Cooeyate, N. J., Hume, D., & Guerra, L. (2024) · Journal of Psychology & Clinical Psychiatry · doi:10.15406/jpcpy.2024.15.00793 · Cited by 1
Depression and Anxiety Disorders
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg003 · Cited by 1
Managing withdrawal symptoms using tapering strips
Groot, P. C., & van Os, J. (2023) · British Journal of General Practice · doi:10.3399/bjgp23x732645 · Cited by 1
Self-citationAbie Horowitz, M., Framer, A., Strang, J., & Taylor, D. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251371504
“63,64 Manufacturers might facilitate this process by producing smaller dose drug formulations.”
Pandiyammal, V., & Raja, U. K. (2020) · Malaya Journal of Matematik · doi:10.26637/mjm0804/0084
Psychotropic medication use in the Armed Forces: prescription patterns and treatment after trauma
Janssen, D. G. A. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/923
Vaaler, A. (2022) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.22.0629
Collaborative Medication Management and Discontinuation
Diamond, R. J., & Sowers, W. E. (2022) · Springer eBooks · doi:10.1007/978-3-031-10239-4_15
Introduction to Deprescribing Psychiatric Medications
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg001
Safe Deprescribing of Benzodiazepines and Z‐drugs
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg003
Safe Deprescribing of Antidepressants
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg002
Safe Deprescribing of Gabapentinoids
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg004
Eserian, J. K., Blanco, V. P., Mercuri, L. P., Matos, J. R., Kalleian, E. A., & Galduróz, J. C. F. (2024) · Pharmacopsychiatry · doi:10.1055/a-2443-1189
Gründer, G. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21199-7.00002-7
Gründer, G. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21199-7.00001-5
General Aspects of Psychopharmacology
Pham, G. S., & Mathew, S. J. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009334730.009
Stratégies et options pharmacologiques
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00008-x
Ferreira, P. M., McDonald, S., Wallis, K. A., & Donald, M. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-116702 · Cited by 1
Hengartner, M. P., Rennwald, A., Senn, O., Neuner-Jehle, S., & Horowitz, M. A. (2026) · Psychotherapy and Psychosomatics · doi:10.1159/pps/aemag002
Rennwald, A., Horowitz, M. A., Senn, O., Neuner-Jehle, S., & Hengartner, M. P. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261492597
Metadata
- Authors
- Groot, P. C., & van Os, J.
- Affiliations
- University Medical Center Utrecht (NL)
- UMC Utrecht Brain Centre, Utrecht, The Netherlands
- Corresponding author
- Groot, Peter C.
- ORCID
- Groot, Peter C.
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2020-01
- Volume
- 10
- Pages
- 2045125320932452-2045125320932452
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC7357127
- OpenAlex
- W3040943896
- Cited by
- 49
- References
- 46
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 13 · 2023: 6 · 2022: 6 · 2021: 10 · 2020: 5
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Health Professions › General Health Professions › Mental Health and Patient Involvement
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- antidepressant discontinuation syndrome, shared decision-making, personalized treatment, patient experience, medication tapering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.